There’s enough evidence from observational and RCT subgroups to stop excluding systematically immunocompromised hosts from duration trials.
Uncomplicated source + early response should always mean shorter.
1 in 3 patients in @shorten2trial.bsky.social is inmunocompromised
bsky.app/profile/jose...
SHORTEN-2 trial
#ShorterIsBetter in immunocompromised hosts?
Short treatments are feasible in early responders without source control issues.
A significant number of observational studies serve as proof-of-concept on the feasibility of short courses in selected patients (see ⚠️)
#AMSsky #IDOnc #TxID #IDsky
